Find trials
Search tips

Patient Outcomes after Intralesional Injections of Collagenase Clostridium Histolyticum for Peyronie's Disease

Overview

About this study

The purpose of this study is to review the outcomes and patient characteristics for our institutional experience with the use of Xiaflex®.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients undergoing intralesional injection of collagenase clostridium histolyticum for Peyronie’s disease

Exclusion Criteria: 

  • None

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Christopher Wolter, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20339563

Mayo Clinic Footer